Sulfaphenazole: Benchmark Competitive CYP2C9 Inhibitor for Drug Metabolism and Vascular Research

Executive Summary: Sulfaphenazole is a potent, competitive inhibitor of cytochrome P450 2C9 (CYP2C9), exhibiting a Ki of 0.3 ± 0.1 μM and high selectivity over related isoforms (APExBIO). It is used to modulate drug metabolism, pharmacogenetic profiling, and adverse drug reaction studies. In vivo, it restores endothelium-dependent vasodilation in diabetic db/db mice by reducing oxidative stress and enhancing nitric oxide bioavailability (Elmi et al., 2008). Sulfaphenazole is insoluble in water but readily soluble in DMSO and ethanol under specified conditions. The compound is approved for research use only, not for diagnostic or clinical applications.

Biological Rationale

CYP2C9 is a major hepatic cytochrome P450 enzyme responsible for metabolizing diverse drugs, including anticoagulants, NSAIDs, and hypoglycemics (APExBIO). Genetic and pharmacological modulation of CYP2C9 activity is crucial for understanding interindividual variation in drug response and adverse reactions. In diabetes and other pathological conditions, upregulation of cytochrome P450 isoforms contributes to oxidative stress and endothelial dysfunction (Elmi et al., 2008). Sulfaphenazole enables selective inhibition of CYP2C9, facilitating mechanistic studies on drug metabolism and vascular pathophysiology.

Mechanism of Action of Sulfaphenazole

Sulfaphenazole is chemically defined as 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide, with a molecular weight of 314.4 and a CAS number of 526-08-9 (APExBIO). It binds competitively to the active site of CYP2C9, inhibiting the enzyme’s activity with a Ki of 0.3 ± 0.1 μM. Sulfaphenazole demonstrates over 10-fold weaker inhibition for CYP2C8 and CYP2C18 and does not inhibit CYP1A1, 1A2, 3A4, or 2C19 (AEBsf.com). This high specificity allows researchers to dissect CYP2C9-mediated pathways without off-target effects on other P450 isoforms. Mechanistically, in diabetic vascular models, CYP2C9 inhibition by Sulfaphenazole reduces superoxide generation and restores nitric oxide-mediated vasodilation (Elmi et al., 2008).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 with a Ki of 0.3 ± 0.1 μM in vitro, confirming nanomolar potency (APExBIO).
• In vivo, daily intraperitoneal administration at 5.13 mg/kg for 8 weeks restored endothelium-dependent vasodilation in diabetic db/db mice (Elmi et al., 2008).
• Treatment reduced plasma 8-isoprostane (oxidative stress marker) and increased plasma NO2− (nitric oxide metabolite) in diabetic mice (Elmi et al., 2008).
• Sulfaphenazole does not affect plasma glucose levels in db/db mice, indicating selective vascular effects (Elmi et al., 2008).
• Limited cross-reactivity: negligible inhibition for CYP1A1, 1A2, 3A4, and 2C19 at practical concentrations (AEBsf.com).
• Sulfaphenazole is insoluble in water but soluble in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, with sonication) (APExBIO).

This article extends prior reviews, such as AEBsf.com, by integrating new in vivo benchmarks and clarifying selectivity under experimental conditions.

Applications, Limits & Misconceptions

Sulfaphenazole is widely used in:

• Drug-drug interaction studies to probe CYP2C9-mediated metabolism (Cytochrome-P450-CYP1B1.com).
• Pharmacogenetic research, especially in variant CYP2C9 backgrounds (Endothelin-1.com).
• Vascular endothelial function studies, particularly in diabetes-induced dysfunction models (Elmi et al., 2008).
• Oxidative stress reduction protocols in preclinical vascular research (Elmi et al., 2008).

While related articles offer strategic benchmarking (Endothelin-1.com), this review details quantitative in vivo outcomes and solubility parameters for robust experimental design.

Common Pitfalls or Misconceptions

• Not suitable for clinical or diagnostic use: Sulfaphenazole is for research use only and is not approved for human or veterinary medicine (APExBIO).
• No effect on CYP3A4 or CYP2C19: At relevant concentrations, it does not inhibit these isoforms; results in these pathways require alternative inhibitors (AEBsf.com).
• Not water-soluble: Direct dissolution in water is ineffective; DMSO or ethanol with ultrasonic assistance is required for stock solutions (APExBIO).
• Long-term solution storage is not recommended: Prepare fresh solutions and store powder at -20°C for optimal stability (APExBIO).
• Species and strain differences: Efficacy and pharmacokinetics may differ outside well-characterized models such as db/db mice (Elmi et al., 2008).

Workflow Integration & Parameters

For in vitro inhibition studies, Sulfaphenazole should be dissolved in DMSO at concentrations up to 13.15 mg/mL. For in vivo research, typical dosing in mice is 5.13 mg/kg by daily intraperitoneal injection for up to 8 weeks. Control groups should match for vehicle effects. Long-term storage of stock solutions is discouraged; fresh preparations from powder (stored at -20°C) are recommended. Refer to the C4131 Sulfaphenazole kit from APExBIO for validated protocols and additional handling guidance.

For comprehensive application notes and troubleshooting, see "Sulfaphenazole: Precision Competitive CYP2C9 Inhibitor for Drug Metabolism and Vascular Dysfunction", which this article updates by explicitly detailing solution stability and selectivity boundaries.

Conclusion & Outlook

Sulfaphenazole remains a gold-standard tool for probing CYP2C9-mediated metabolism and vascular dysfunction, with well-characterized potency and selectivity. Its use in diabetic vascular models underscores its value in oxidative stress and endothelial function studies. Ongoing research is refining application guidelines for diverse pharmacogenetic and adverse drug reaction models. For up-to-date product specifications and protocols, consult APExBIO.